Q2 2025 Hologic Inc Earnings Call Transcript
Key Points
- Hologic Inc (HOLX) reported total revenue of $1.005 billion for the quarter, which was toward the upper end of their guidance.
- Non-GAAP earnings per share were $1.03, at the high end of the guidance range, reflecting solid gross margin expansion.
- The Diagnostics business showed strong growth, particularly in molecular diagnostics, with a 5.2% increase excluding COVID-related sales.
- The company has a strong balance sheet with $1.43 billion in cash and equivalents, providing strategic and financial flexibility.
- Hologic Inc (HOLX) has a highly engaged workforce, with employee engagement scores in the 98th percentile compared to similar companies.
- Total revenue decreased by 0.5% in constant currency, indicating a slight decline compared to the previous year.
- The Breast Health segment experienced a revenue decline of 6.9%, with challenges in gantry replacements and market conditions.
- The company is facing increased costs due to tariffs, with an estimated impact of $20 million to $25 million per quarter.
- Sales expectations for China have been lowered due to geopolitical turbulence, impacting overall revenue forecasts.
- Funding cuts in Africa have led to a significant disruption in the Diagnostics business, particularly affecting HIV testing.
Good afternoon, and welcome to Hologic's Second Quarter Fiscal 2025 Earnings Conference Call. My name is Rachel, and I'm your operator for today's call. Today's conference is being recorded.
I would now like to introduce Mike Watts to begin the call.
Thank you, Rachel. Good afternoon, and thank you for joining Hologic's Second Quarter Fiscal 2025 Earnings Call. With me today are Steve MacMillan, the company's Chairman, President and Chief Executive Officer; Essex Mitchell, our Chief Operating Officer; and Karleen Oberton, our Chief Financial Officer.
Our second quarter press release is available now on the Investors section of our website. We will also post our prepared remarks to our website shortly after we deliver them, and a replay of this call will be available for 30 days.
Before we begin, we'd like to inform you that certain statements we make today will be forward-looking. These statements include known and unknown risks and uncertainties that may cause
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
